Form D · Pharmaceuticals
Vitalis Therapeutics, Inc.
New York, NY · CIK 0002026886
Offering snapshot reported Feb 19, 2025 · SEC filing
- Reported sold
- $1.95M Offering amount: $3M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 13, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 19, 2025 | Initial | $1,954,956 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-538561
Source: Form D, filed Feb 19, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph Habboushe | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
93 4 Th Avenue, #19
New York, NY, 10003
Phone: 646-831-7338
New York, NY, 10003
Phone: 646-831-7338